BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  BioMidwest

  Recalled Eli Lilly Glucagon Kits Were Manufactured at Factory with Troubled Past

  Eli Lilly investigators said there might have been an error in the manufacturing process of lot D239382D but did not elaborate further.

  October 5, 2021

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Drug Development

  First Long-Acting Antibody Cocktail to Prevent COVID-19 Submitted for EUA

  AstraZeneca submitted data for an Emergency Use Authorization for AZD7442, a long-acting antibody combination from B-cells donated by patients who recovered from COVID-19.

  October 5, 2021

   · 

  3 min read

   · 

  Mark Terry
• 

  FDA

  COVID News: J&J Booster Hopes, Waning Immunity, Anti-Vax Paper Retracted and More

  There is — still — plenty of news about COVID-19 and new drugs, therapies and FDA applications. Here’s a look.

  October 5, 2021

   · 

  4 min read

   · 

  Mark Terry
• 

  Pharm Country

  Merck’s Molnupiravir and the Monetary Cost of COVID-19

  There is a noted discrepancy between the price the U.S. government has agreed to pay Merck for the drug and the actual manufacturing costs.

  October 5, 2021

   · 

  3 min read

   · 

  Heather McKenzie
• 

  Policy

  Thermo Fisher Sued Over Profiting from “Stolen” HeLa Cell Line

  Henrietta Lacks’ family accuses Thermo Fisher Scientific of profiting off the first cell line that had been shared and replicated in a lab for the development of countless medical innovations.

  October 5, 2021

   · 

  2 min read

   · 

  Alex Keown
• 

  Business

  Colossal Wants to Bring Back the Woolly Mammoth. Should It?

  The idea is not just a flight of fancy by a brilliant mind with big dreams. It is part of a larger de-extinction strategy aimed at solving climate change.

  October 5, 2021

   · 

  4 min read

   · 

  Heather McKenzie
• 

  Drug Development

  Rejuvenate Bio is Reversing Age-Related Diseases to Increase Healthspan

  Unlike most companies addressing the diseases associated with aging, Rejuvenate Bio tackles multiple cardiac, metabolic and renal issues at once.

  October 5, 2021

   · 

  5 min read

   · 

  Gail Dutton
• 

  Business

  Collins Calls Time for a Change, Steps Down as NIH Director

  After serving three presidential administrations, Dr. Francis S. Collins is stepping down as director of the National Institutes of Health at the end of the year.

  October 5, 2021

   · 

  3 min read

   · 

  Alex Keown
• 

  Personalized, Deep Brain Stimulation Gives One Patient a New Lease on Life

  Researchers at UCSF believed that a more personalized, deep brain stimulation could be a key. While DBS isn’t new, the UCSF team’s approach in their recently released study was unique.

  October 5, 2021

   · 

  3 min read

   · 

  Kate Goodwin
• 

  Genetown

  Exo Rakes In $78 Million Series B for Enzyme Inhibitors

  Novartis-backed Exo Therapeutics closed out 2020 by completing a $25 million Series A financing round. Nearly 10 months later, the small molecule drug discovery and development company has earned more support from investors.

  October 5, 2021

   · 

  1 min read

   · 

  Ellen Camacho